Background: Monomethylsilanetriol (MMST) has been used for decades as an oral silicon supplement for bone and connective tissue health, although there are no formal data on its in vivo utilisation or safety following sustained dosing.
Methods: To investigate whether MMST contributes to the body pool of silicon and, secondly, to establish its safety following 4 weeks' supplementation in humans, twenty-two healthy pre-menopausal women (22-38 years) were recruited and supplemented with MMST at the maximum daily recommended dose (10.5 mg Si/day) for 4 weeks in a double-blind, randomised, placebo-controlled, cross-over design (i.